Cargando…
Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673129/ https://www.ncbi.nlm.nih.gov/pubmed/29177233 http://dx.doi.org/10.1097/IJ9.0000000000000040 |
Ejemplares similares
-
Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017) -
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017) -
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
por: Schernthaner, G, et al.
Publicado: (2013) -
Erratum. Metformin Use in Prediabetes Among U.S. Adults, 2005–2012. Diabetes Care 2017;40:887–893
por: Tseng, Eva, et al.
Publicado: (2018) -
Erratum. Glucolipotoxicity-Inhibited miR-299-5p Regulates Pancreatic β-Cell Function and Survival. Diabetes 2018;67:2280–2292
por: Huang, Qiqing, et al.
Publicado: (2019)